Ann: China and Japan both grant patents for Deoxymab 3E10, page-2

Patents Granted for Deoxymab 3E10 Family in both Japan and China Melbourne, Australia; July 3, 2018: Patrys Limited (ASX: PAB), a therapeutic antibody development company, is pleased to announce that it has received Notices of Grant from both the Japanese and Chinese Patent Offices for the patent titled “Cell-penetrating anti-DNA antibodies and uses thereof to inhibit DNA repair” (Patent numbers 6178785 (JP) and ZL 201280025431.2 (CN)). The patent is directed towards methods of using Patrys’ novel Deoxymab 3E10 technology, including Patrys’ lead candidate, PAT-DX1, as treatment for various cancers and malignancies including gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers. Following grant in the U.S. of the first patent in the 3E10 portfolio in July 2017, both the Japanese and Chinese patents extend the intellectual property base of the Company. “Grant of patents in the USA, Japan and China establishes strong intellectual property rights for the 3E10 technology in the world’s three largest pharmaceutical markets, and is another important step for Patrys.” said Dr. James Campbell, Chief Executive Officer and Managing Director of Patrys. “Patrys has made significant progress with its pre-clinical development of PAT-DX1 over the past year, including confirmation that PAT-DX1 can cross the blood-brain barrier, and improve survival in a mouse model of glioblastoma. Following-on from $4.6 million capital raise in May, the Company is in a strong position to achieve further milestones this year and we look forward to providing updates on our progress over the coming months.” About Deoxymab 3E10, PAT-DX1 and PAT-DX1-NP Deoxymab 3E10 is a DNA damage-repair (DDR) antibody that was first identified in lupus as an autoantibody that bound to normal cells. Of particular interest is that whilst most antibodies bind to cell surface markers, Deoxymab 3E10 penetrates into the cell nuclei and binds directly to DNA where it inhibits DNA repair processes and kills cells that have mutations or deficiencies in DNA repair mechanisms as found in various cancer cells. Deoxymab 3E10 has single agent therapeutic potential and has been shown to significantly enhance the efficacy of both chemo- and radiotherapies. Further, Deoxymab 3E10 can be conjugated to nanoparticles to target delivery of chemotherapeutics and imaging agents to tumors. Patrys has developed a humanized form of Deoxymab 3E10, PAT-DX1 with improved activity over the original version of 3E10, and is progressing this, and a nanoparticle-conjugated form (PAT-DX1-NP) towards the clinic. In a range of pre-clinical cancer models PAT-DX1 has shown significant ability to kill cancer cells in cell models, human tumor explants and xenograft models. PAT-DX1 has also been shown to work synergistically with the approved PARP inhibitor, olaparib. Patrys believes that PATDX1 may have application across a wide range of malignancies such as gliomas, melanomas, prostate, breast, pancreatic and ovarian cancers. 2 Patrys’ rights to Deoxymab 3E10 are part of a worldwide license to develop and commercialize as anticancer and diagnostic agents a portfolio of novel anti-DNA antibodies and antibody fragments, variants and conjugates discovered at Yale University.